Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biogen Idec
(NQ:
BIIB
)
194.67
+1.07 (+0.55%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biogen Idec
< Previous
1
2
...
28
29
30
31
32
33
34
35
36
...
47
48
Next >
BIIB Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Biogen, Inc. Investors of Class Action and Encourages Investors to Contact the Firm
February 11, 2022
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Shareholder Alert: Robbins LLP Reminds Investors Biogen, Inc. (BIIB) is Being Sued for Misleading Shareholders
February 11, 2022
From
Robbins LLP
Via
Business Wire
Biogen Shareholder Notice
February 10, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
BIOGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Biogen, Inc. and Encourages Investors to Contact the Firm
February 09, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
What 24 Analyst Ratings Have To Say About Biogen
February 04, 2022
Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following analyst ratings:
Via
Benzinga
Biogen Shareholder Alert
February 09, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
CORRECTING and REPLACING Shareholder Alert: Robbins LLP Informs Investors Biogen, Inc. (BIIB) is Being Sued for Misleading Shareholders
February 09, 2022
From
Robbins LLP
Via
Business Wire
Shareholder Alert: Robbins LLP Informs Investors Biogen, Inc. (BIIB) is Being Sued for Misleading Shareholders
February 09, 2022
From
Robbins LLP
Via
Business Wire
Analyst Ratings For Biogen
February 04, 2022
Analysts have provided the following ratings for Biogen (NASDAQ:BIIB) within the last quarter:
Via
Benzinga
Biogen: Q4 Earnings Insights
February 03, 2022
Biogen (NASDAQ:BIIB) reported its Q4 earnings results on Thursday, February 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Biogen's Alzheimer's Struggles Continue; 'Minimal' Sales Expected This Year
February 03, 2022
Biogen's new Alzheimer's drug generated $1 million in fourth-quarter sales.
Via
Investor's Business Daily
Recap: Biogen Q4 Earnings
February 03, 2022
Biogen (NASDAQ:BIIB) reported its Q4 earnings results on Thursday, February 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Biogen Deadline Alert
February 08, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Biogen-Xbrane Enter License Agreement For Cimzia Referenced Biosimilar, Xcimzane
February 08, 2022
Biogen Inc (NASDAQ: BIIB) and Xbrane Biopharma AB have
Via
Benzinga
The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar
February 08, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
10 Biggest Price Target Changes For Monday
February 07, 2022
BMO Capital cut the price target for Match Group, Inc. (NASDAQ: MTCH) from $150 to $130. Match Group shares fell 1.4% to trade at $114.33 on Monday.
Via
Benzinga
Earnings Scheduled For February 3, 2022
February 03, 2022
Companies Reporting Before The Bell • Tuesday Morning (NASDAQ:TUEM) is likely to report earnings for its second quarter.
Via
Benzinga
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, & More
February 06, 2022
Biotech stocks managed to close the week with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid some big pharma earnings. The sector came...
Via
Talk Markets
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
February 06, 2022
Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big...
Via
Benzinga
Biogen's Aduhelm Approval, Marketing Comes Under FTC, SEC Probes
February 04, 2022
The Federal Trade Commission (FTC) and the Securities and Exchange Commission (SEC) have launched two separate investigations into Biogen Inc (NASDAQ: BIIB) and its Alzheimer's med, Aduhelm...
Via
Benzinga
Stock Market Rally Volatile; Google, Facebook, Amazon, Snap Are Earnings Movers: Weekly Review
February 04, 2022
The major indexes slashed weekly gains after Monday's follow-through day.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For February 4, 2022
February 04, 2022
Upgrades CBRE upgraded the previous rating for Penn National Gaming Inc (NASDAQ:PENN) from Hold to Buy. For the fourth quarter, Penn National Gaming had an EPS of $0.26,...
Via
Benzinga
10 Biggest Price Target Changes For Friday
February 04, 2022
JP Morgan boosted the price target for Amazon.com, Inc. (NASDAQ: AMZN) from $4,350 to $4,500. Amazon shares jumped 11% to $3,081.07 in pre-market trading.
Via
Benzinga
Facebook FB plunges but Amazon AMZN surges: Earnings and Your Updated Price Levels
February 03, 2022
It seems like yesterday we were discussing the surge in Alphabet shares, and today we're focusing on big moves - currently in opposite directions - of Facebook and Amazon, all major market cap...
Via
Talk Markets
Biogen's Alzheimer's Drug Clocks Q4 Sales Of Just $1M, FY22 Earnings Guidance Below Consensus
February 03, 2022
Biogen Inc (NASDAQ: BIIB) posted Q4 sales of 2.73 billion, beating the consensus of $
Via
Benzinga
The Daily Biotech Pulse: Big Pharma Earnings Prove Lackluster, Mersana Inks $1B ADC R&D Deal, Syros Gets Orphan Drug Designation
February 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
February 03, 2022
On Thursday, 105 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows And Highs: Meta Platforms (NASDAQ:FB) was the biggest company on...
Via
Benzinga
Earnings Preview For Biogen
February 02, 2022
Biogen (NASDAQ:BIIB) is set to give its latest quarterly earnings report on Thursday, 2022-02-03. Here's what investors need to know before the announcement. Analysts estimate that Biogen will likely...
Via
Benzinga
World Markets News for Tuesday
February 01, 2022
Exxon is splitting into 3 with its new restructuring move: upstream; chemicals; and low-carbon.
Via
Talk Markets
Biogen Exercises Option To Participate Developing Genentech's Bispecific Antibody, Mosunetuzumab
February 01, 2022
Biogen Inc (NASDAQ: BIIB) has
Via
Benzinga
< Previous
1
2
...
28
29
30
31
32
33
34
35
36
...
47
48
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.